Venezuelan equine encephalitis virus envelope protein (VEEV envelope protein)

The Venezuelan equine encephalitis virus (VEEV) envelope proteins—primarily E1 and E2—are surface glycoproteins of the VEEV virion, an enveloped, positive-sense single-stranded RNA alphavirus of the *Togaviridae* family[1][3][5]. These glycoproteins mediate critical steps in the viral life cycle, including attachment to host cellular receptors, membrane fusion, and virion assembly[1][3]. The E2 protein predominantly engages entry factors on host cells, while E1 is essential for the fusion process within endosomal compartments[3]. Both proteins are immunogenic and represent the primary antigens for host antibody responses during infection and vaccination[1][3]. The “target” in the provided phrase—“immune system stimulation via presentation of Venezuelan equine encephalitis virus envelope protein antigens”—refers to the host's immune response to these viral proteins, rather than to a single human molecular target such as a receptor or enzyme. Thus, this is not a canonical therapeutic target but rather encompasses a viral antigen used for immunization or research[3][5]. **Assessment**: - This entry is incorrectly formatted as a “target” in the usual sense, as it specifies a mechanism (immune stimulation via antigen presentation) rather than a discrete molecule (e.g., a receptor or enzyme). - The canonical target here should be the specific VEEV envelope protein or its subunits (E1 or E2 protein), not an immunological process. - If structured information is needed, VEEV E1 or E2 envelope glycoprotein should be the canonical molecule, which are viral proteins and not host molecular targets. **Supporting details**: - VEEV is an important zoonotic pathogen and potential biothreat agent; its envelope glycoproteins are central to both viral infectivity and immune recognition[1][3]. - These proteins do not interact with known therapeutic drugs directly; rather, they are relevant as vaccine antigens and for the development of neutralizing antibodies[3]. - Presentation of VEEV envelope proteins by antigen-presenting cells stimulates adaptive immunity during infection or vaccination, forming the rationale for their use in vaccine design[3]. **Summary**: The phrase describes immunological targeting of VEEV envelope proteins but does not refer to a canonical human therapeutic target; standardized forms would be "Venezuelan equine encephalitis virus E1 envelope glycoprotein" or "Venezuelan equine encephalitis virus E2 envelope glycoprotein"[1][3][5].

Other names

VEEV E1 proteinVEEV E2 proteinVEEV E1/E2 envelope glycoproteinAlphavirus envelope protein